Forbes

Generate Biomedicines IPO Turns Heads

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...
Morningstar

How to Turn Any Image into a Full-Color 3D Print in One Click — Meshy's Multi-Color Printing, Powered by Meshy-6, Is Now Live on MakerWorld

Meshy integrates its Image-to-3D tool into Bambu Lab's MakerWorld MakerLab, while also launching Multi-Color Printing on meshy.ai — together delivering the most seamless AI-to-print workflow on the ...
MedCity News

Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...
Reuters

Drug developer Generate Biomedicines raises $400 million in US IPO

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...
The Boston Globe

Flagship-backed Generate Biomedicines seeks $425 million in IPO

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...
The Business Journals

Generate:Biomedicines targets $400M IPO amid biotech market thaw

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Somerville company aims to ...
Seeking Alpha

Generate Biomedicines Begins IPO Push With Major Collaboration Deals

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...
FierceBiotech

Flagship-founded antibody biotech Generate is latest to mull IPO

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...
The Business Journals

Generate:Biomedicines eyes public markets as AI drug advances to late-stage trials

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...
Bloomberg L.P.

Flagship-Backed Drug Firm Generate Biomedicines Files for US IPO

Generate Biomedicines Inc. filed for an initial public offering, joining a growing list of biotechnology firms to leap to public markets as investors embrace the sector. The Somerville, ...
The New York Times

Can A.I. Generate New Ideas?

Systems like OpenAI’s GPT-5 are accelerating research in math, biology and chemistry. But there is a debate over whether it can do that work on its own. Credit...Agnes Jonas Supported by By Cade Metz ...